TY  - JOUR
AU  - Le Cornet, Charlotte
AU  - Jung, Audrey Ying-Chee
AU  - Behrens, Sabine
AU  - Middha, Pooja
AU  - Truong, Thérèse
AU  - Jernström, Helena
AU  - Bolla, Manjeet K
AU  - Wang, Qin
AU  - Southey, Melissa C
AU  - Beane Freeman, Laura E
AU  - Koutros, Stella
AU  - Stone, Jennifer
AU  - Rennert, Gad
AU  - Shulman, Katerina
AU  - Aronson, Kristan J
AU  - Murphy, Rachel A
AU  - Guénel, Pascal
AU  - Patel, Alpa V
AU  - Bodelon, Clara
AU  - Teras, Lauren R
AU  - Shahi, Shamim
AU  - Lacey, James V
AU  - Dossus, Laure
AU  - Kaaks, Rudolf
AU  - Holleczek, Bernd
AU  - Brenner, Hermann
AU  - Brauch, Hiltrud
AU  - Hoppe, Reiner
AU  - Czene, Kamila
AU  - Hall, Per Frans Leonard
AU  - Mannermaa, Arto
AU  - Wu, Anna H
AU  - Obi, Nadia
AU  - Michailidou, Kyriaki
AU  - Panayiotidis, Mihalis I
AU  - McLean, Catriona
AU  - Haiman, Christopher A
AU  - Augustinsson, Annelie
AU  - Zheng, Wei
AU  - Shu, Xiao-Ou
AU  - Perou, Charles M
AU  - Troester, Melissa A
AU  - Van Alsten, Sarah
AU  - Eliassen, A Heather
AU  - Abubakar, Mustapha
AU  - Kraft, Peter
AU  - Ahearn, Thomas U
AU  - Evans, D Gareth
AU  - Wolk, Alicja
AU  - Milne, Roger L
AU  - Easton, Douglas F
AU  - Pharoah, Paul D P
AU  - Schmidt, Marjanka K
AU  - García-Closas, Montserrat
AU  - Vachon, Celine M
AU  - Turzanski-Fortner, Renée
AU  - Chang-Claude, Jenny
TI  - Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer.
JO  - JAMA network open
VL  - 8
IS  - 7
SN  - 2574-3805
CY  - Chicago, Ill.
PB  - American Medical Association
M1  - DKFZ-2025-01356
SP  - e2519236
PY  - 2025
N1  - #EA:C020#LA:C020#
AB  - Etiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood.To examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes.This study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024.MHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use).Breast cancer intrinsic-like subtypes (luminal A-like, luminal B-like, luminal B-ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched-like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5-<25; overweight, 25-<30; or obesity, ≥30).This study included 42 269 individuals with breast cancer (11 901 [28.2
KW  - Humans
KW  - Female
KW  - Breast Neoplasms: epidemiology
KW  - Breast Neoplasms: classification
KW  - Breast Neoplasms: chemically induced
KW  - Breast Neoplasms: pathology
KW  - Middle Aged
KW  - Case-Control Studies
KW  - Postmenopause
KW  - Adult
KW  - Prospective Studies
KW  - Aged
KW  - Contraceptives, Oral: adverse effects
KW  - Premenopause
KW  - Estrogen Replacement Therapy: adverse effects
KW  - Estrogen Replacement Therapy: statistics & numerical data
KW  - Contraceptives, Oral (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40622713
C2  - pmc:PMC12235495
DO  - DOI:10.1001/jamanetworkopen.2025.19236
UR  - https://inrepo02.dkfz.de/record/302816
ER  -